Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 124Myelodysplastic Syndromes 119Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 85Hodgkin Disease 80Leukemia, Lymphocytic, Chronic, B-Cell 77Lymphoma 75Multiple Myeloma 74Lymphoma, Non-Hodgkin 74Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 53Lymphoma, Mantle-Cell 49Lymphoma, Large B-Cell, Diffuse 49Leukemia, Myeloid, Accelerated Phase 49Leukemia, Myelomonocytic, Chronic 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Congenital Abnormalities 47Hematologic Neoplasms 45Leukemia, Myeloid, Chronic-Phase 44Lymphoma, B-Cell, Marginal Zone 43Primary Myelofibrosis 41Burkitt Lymphoma 41Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 33Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

gamma-Globulins 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Paraneoplastic Syndromes × Tacrolimus × Clear all
NCT00378326 2023-09-18

Immunotherapy of the Paraneoplastic Syndromes

Rockefeller University

Phase NA Completed
26 enrolled 6 charts

Paraneoplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡